FULC Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

$14.00  +0.93 (7.08%)
As of 03/02/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
07/18/2019
32,667,434
114,256
$426,963,362
0.00%
SEC Edgar Online
10-Q
10-K
359616109
US3596161097
BJDX8Z9

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-8.04
2.89
92.86
-65.94%
-1,505.48%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy